ABX464 reduces HIV reservoirs in Ph IIa trial

Abivax S.A.S. (Euronext:ABVX) said ABX464 for 28 days reduced HIV reservoirs as measured by total HIV DNA detected in peripheral blood mononuclear cells (PBMCs) in the Phase IIa ABX464-004 trial to treat HIV infection. Specifically, 7 of 14 evaluable chronically infected HIV patients who received ABX464 achieved a reduction in total HIV DNA in PBMCs of ≥25% and a reduction of at least 50 copies compared to 0 of 4 patients who received placebo. ABX464 was well tolerated with no severe adverse events reported.

Patients received placebo or once-daily 50 and 150 mg ABX464 in addition to their current antiretroviral therapy (ART) consisting of Prezista darunavir plus ritonavir or Prezista pus Tybost cobicistat. At day 28, all treatment was interrupted until viral load rebound. Patients' viral load at the start of the trial was well controlled with boosted Prezista. The primary endpoint of the double-blind, European trial, which enrolled 30 patients, is safety and the secondary endpoint is time to viral rebound...